Fdc Share Price
Sector: Biotechnology & Drugs
471.90 +0.70 (0.15%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
471.90
Today’s High
476.85
52 Week Low
358.95
52 Week High
659
472.40 +0.65 (0.14%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
471
Today’s High
476.10
52 Week Low
366.25
52 Week High
658.85
Key Metrics
- Market Cap (In Cr) 7665.34
- Beta 0.6
- Div. Yield (%) 1.06
- P/B 3.37
- TTM P/E 24.02
- Peg Ratio 3.37
- Sector P/E 22.65
- D/E 0
- Open Price 472.8
- Prev Close 471.2
Fdc Analysis
Price Analysis
-
1 Week0.72%
-
3 Months21.68%
-
6 Month-5.57%
-
YTD-5.55%
-
1 Year1.85%
Risk Meter
- 31% Low risk
- 31% Moderate risk
- 31% Balanced Risk
- 31% High risk
- 31% Extreme risk
Fdc News
Recommended stocks to buy today, 16 June, by India's leading market experts
6 min read . 16 Jun 2025Q4 results today: IRCTC, Deepak Nitrate, SAIL, Cummins, Bata India on May 28
2 min read . 28 May 2025Fdc Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 2108.12
- Selling/ General/ Admin Expenses Total
- 482.37
- Depreciation/ Amortization
- 53.73
- Other Operating Expenses Total
- 564.68
- Total Operating Expense
- 1837.05
- Operating Income
- 271.07
- Net Income Before Taxes
- 357.22
- Net Income
- 266.79
- Diluted Normalized EPS
- 16.39
- Period
- 2025
- Total Assets
- 2713.8
- Total Liabilities
- 432.72
- Total Equity
- 2281.08
- Tangible Book Valueper Share Common Eq
- 139.85
- Period
- 2025
- Cashfrom Operating Activities
- 317.57
- Cashfrom Investing Activities
- -199.51
- Cashfrom Financing Activities
- -92.12
- Net Changein Cash
- 26.05
- Period
- 2024
- Total Revenue
- 1942.94
- Selling/ General/ Admin Expenses Total
- 808.15
- Depreciation/ Amortization
- 39.92
- Other Operating Expenses Total
- 20.96
- Total Operating Expense
- 1644.32
- Operating Income
- 298.62
- Net Income Before Taxes
- 396.22
- Net Income
- 305.22
- Diluted Normalized EPS
- 18.38
- Period
- 2024
- Total Assets
- 2468.09
- Total Liabilities
- 370.92
- Total Equity
- 2097.17
- Tangible Book Valueper Share Common Eq
- 128.55
- Period
- 2024
- Cashfrom Operating Activities
- 220.77
- Cashfrom Investing Activities
- -17.08
- Cashfrom Financing Activities
- -202.16
- Net Changein Cash
- 1.53
- Period
- 2023
- Total Revenue
- 1783.75
- Selling/ General/ Admin Expenses Total
- 751.53
- Depreciation/ Amortization
- 38.94
- Other Operating Expenses Total
- 17.03
- Total Operating Expense
- 1571.72
- Operating Income
- 212.04
- Net Income Before Taxes
- 257.8
- Net Income
- 194.04
- Diluted Normalized EPS
- 11.63
- Period
- 2023
- Total Assets
- 2342.94
- Total Liabilities
- 360.89
- Total Equity
- 1982.05
- Tangible Book Valueper Share Common Eq
- 119.2
- Period
- 2023
- Cashfrom Operating Activities
- 154.91
- Cashfrom Investing Activities
- 11.13
- Cashfrom Financing Activities
- -179.95
- Net Changein Cash
- -13.84
- Period
- 2022
- Total Revenue
- 1527.92
- Selling/ General/ Admin Expenses Total
- 642.69
- Depreciation/ Amortization
- 37.3
- Other Operating Expenses Total
- 15.24
- Total Operating Expense
- 1311.53
- Operating Income
- 216.38
- Net Income Before Taxes
- 289.39
- Net Income
- 216.4
- Diluted Normalized EPS
- 12.78
- Period
- 2022
- Total Assets
- 2270.2
- Total Liabilities
- 313.41
- Total Equity
- 1956.79
- Tangible Book Valueper Share Common Eq
- 115.64
- Period
- 2022
- Cashfrom Operating Activities
- 161.65
- Cashfrom Investing Activities
- -144.57
- Cashfrom Financing Activities
- -9.84
- Net Changein Cash
- 7.29
- Period
- 2021
- Total Revenue
- 1333.2
- Selling/ General/ Admin Expenses Total
- 486.56
- Depreciation/ Amortization
- 37.81
- Other Operating Expenses Total
- 31.42
- Total Operating Expense
- 1039.09
- Operating Income
- 294.12
- Net Income Before Taxes
- 387.73
- Net Income
- 301.35
- Diluted Normalized EPS
- 17.79
- Period
- 2021
- Total Assets
- 1956.23
- Total Liabilities
- 222.1
- Total Equity
- 1734.13
- Tangible Book Valueper Share Common Eq
- 102.47
- Period
- 2021
- Cashfrom Operating Activities
- 207.08
- Cashfrom Investing Activities
- -77.15
- Cashfrom Financing Activities
- -129.35
- Net Changein Cash
- 0.55
- Period
- 2020
- Total Revenue
- 1344.19
- Selling/ General/ Admin Expenses Total
- 509.35
- Depreciation/ Amortization
- 37.46
- Other Operating Expenses Total
- 38.99
- Total Operating Expense
- 1063.77
- Operating Income
- 280.43
- Net Income Before Taxes
- 320.97
- Net Income
- 239.88
- Diluted Normalized EPS
- 13.17
- Period
- 2020
- Total Assets
- 1812.93
- Total Liabilities
- 265.5
- Total Equity
- 1547.43
- Tangible Book Valueper Share Common Eq
- 90.14
- Period
- 2020
- Cashfrom Operating Activities
- 250.38
- Cashfrom Investing Activities
- -98.35
- Cashfrom Financing Activities
- -142
- Net Changein Cash
- 9.96
- Period
- 2019
- Total Revenue
- 1090.7
- Selling/ General/ Admin Expenses Total
- 422.28
- Depreciation/ Amortization
- 33.24
- Other Operating Expenses Total
- 42.47
- Total Operating Expense
- 894.04
- Operating Income
- 196.66
- Net Income Before Taxes
- 236.64
- Net Income
- 169.79
- Diluted Normalized EPS
- 9.77
- Period
- 2019
- Total Assets
- 1639.88
- Total Liabilities
- 194.65
- Total Equity
- 1445.24
- Tangible Book Valueper Share Common Eq
- 82.5
- Period
- 2019
- Cashfrom Operating Activities
- 112.43
- Cashfrom Investing Activities
- -120.33
- Cashfrom Financing Activities
- -0.07
- Net Changein Cash
- -8.21
- Period
- 2025-03-31
- Total Revenue
- 491.89
- Selling/ General/ Admin Expenses Total
- 121.61
- Depreciation/ Amortization
- 15.56
- Other Operating Expenses Total
- 154.96
- Total Operating Expense
- 453.47
- Operating Income
- 38.42
- Net Income Before Taxes
- 53.31
- Net Income
- 38.67
- Diluted Normalized EPS
- 2.38
- Period
- 2025-03-31
- Total Assets
- 2713.8
- Total Liabilities
- 432.72
- Total Equity
- 2281.08
- Tangible Book Valueper Share Common Eq
- 139.85
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 317.57
- Cashfrom Investing Activities
- -199.51
- Cashfrom Financing Activities
- -92.12
- Net Changein Cash
- 26.05
- Period
- 2024-12-31
- Total Revenue
- 464.11
- Selling/ General/ Admin Expenses Total
- 118.6
- Depreciation/ Amortization
- 13.36
- Other Operating Expenses Total
- 137.94
- Total Operating Expense
- 430.82
- Operating Income
- 33.3
- Net Income Before Taxes
- 51.18
- Net Income
- 37.04
- Diluted Normalized EPS
- 2.28
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 513.85
- Selling/ General/ Admin Expenses Total
- 124.95
- Depreciation/ Amortization
- 13.79
- Other Operating Expenses Total
- 135.7
- Total Operating Expense
- 457.48
- Operating Income
- 56.37
- Net Income Before Taxes
- 90
- Net Income
- 72.04
- Diluted Normalized EPS
- 4.43
- Period
- 2024-09-30
- Total Assets
- 2688.08
- Total Liabilities
- 396.35
- Total Equity
- 2291.73
- Tangible Book Valueper Share Common Eq
- 140.5
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 224.7
- Cashfrom Investing Activities
- -200
- Cashfrom Financing Activities
- -5.72
- Net Changein Cash
- 19
- Period
- 2024-06-30
- Total Revenue
- 638.27
- Selling/ General/ Admin Expenses Total
- 117.21
- Depreciation/ Amortization
- 11.02
- Other Operating Expenses Total
- 143.46
- Total Operating Expense
- 502.68
- Operating Income
- 135.59
- Net Income Before Taxes
- 162.73
- Net Income
- 119.04
- Diluted Normalized EPS
- 7.31
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 462.03
- Selling/ General/ Admin Expenses Total
- 103.24
- Depreciation/ Amortization
- 10.44
- Other Operating Expenses Total
- 149.1
- Total Operating Expense
- 416.14
- Operating Income
- 45.89
- Net Income Before Taxes
- 65.21
- Net Income
- 46.28
- Diluted Normalized EPS
- 2.76
- Period
- 2024-03-31
- Total Assets
- 2468.09
- Total Liabilities
- 370.92
- Total Equity
- 2097.17
- Tangible Book Valueper Share Common Eq
- 128.55
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 220.77
- Cashfrom Investing Activities
- -17.08
- Cashfrom Financing Activities
- -202.16
- Net Changein Cash
- 1.53
- Period
- 2023-12-31
- Total Revenue
- 458.17
- Selling/ General/ Admin Expenses Total
- 103.51
- Depreciation/ Amortization
- 9.97
- Other Operating Expenses Total
- 120.11
- Total Operating Expense
- 384.35
- Operating Income
- 73.82
- Net Income Before Taxes
- 97.55
- Net Income
- 79.23
- Diluted Normalized EPS
- 4.86
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Fdc Technical
Moving Average
SMA
- 5 Day462.85
- 10 Day463.68
- 20 Day452.6
- 50 Day442.08
- 100 Day430.97
- 300 Day477.4
Fdc Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Procter & Gamble Health
- 5916.05
- 7.45
- 0.13
- 6107.55
- 4912.3
- 9830.17
- Shilpa Medicare
- 868.9
- 14.15
- 1.66
- 1003.2
- 530.5
- 8497.05
- Fdc
- 471.9
- 0.7
- 0.15
- 659
- 358.95
- 7665.34
- Aarti Pharmalabs
- 875.35
- 9.65
- 1.11
- 948.8
- 521
- 7929.06
- Strides Pharma Science
- 888.2
- -1.95
- -0.22
- 901.75
- 412.71
- 8188.35
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Procter & Gamble Health
- 45.08
- 18.24
- -
- -
- Shilpa Medicare
- 87.4
- 3.56
- 3.27
- 5.17
- Fdc
- 29.14
- 3.41
- 13.26
- 14.75
- Aarti Pharmalabs
- 28.4
- 3.89
- -
- -
- Strides Pharma Science
- 21.83
- 3.01
- -1.22
- -1.07
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 28-May-25
- Audited Results
- 12-Feb-25
- Quarterly Results & Others
- 06-Nov-24
- Quarterly Results & Others
- 07-Aug-24
- Quarterly Results
- 29-May-24
- Audited Results
- 07-Feb-24
- Quarterly Results
- 08-Nov-23
- Quarterly Results
- 09-Aug-23
- Quarterly Results & Buy Back of shares
- 25-May-23
- Audited Results
- 09-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 26-Sept-24
- 06-Sept-24
- AGM
- 23-Jul-24
- 19-Jun-24
- POM
- 27-Sept-23
- 30-Aug-23
- AGM
- 17-Jul-23
- 13-Jun-23
- POM
- -
- 09-Feb-22
- Others
- -
- 09-Aug-23
- Others
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 07-Nov-24
- 22-Nov-24
- 22-Nov-24
- 5


